As someone who works at the bioinformatics end of a clinical cancer sequencing operation, and someone familiar with the  MSKCC operation (they are doing good work with their IMPACT assay) I have to say that the landscape of matching patients with drugs is so sparse (few drugs, few FDA-approved links, not enough trials) that no Watson is necessary, <i>just</i> basic string matching and a comprehensive high-quality up-to-date database (which does not exist and currently there are 10+ companies working on it)